Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lessened its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 31.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,905 shares of the company’s stock after selling 15,396 shares during the period. Intech Investment Management LLC’s holdings in Henry Schein were worth $2,399,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Cromwell Holdings LLC lifted its position in Henry Schein by 93.4% in the third quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock valued at $26,000 after buying an additional 170 shares during the last quarter. Summit Securities Group LLC purchased a new position in shares of Henry Schein during the 2nd quarter worth approximately $31,000. Beach Investment Counsel Inc. PA acquired a new stake in Henry Schein in the 2nd quarter valued at approximately $37,000. Blue Trust Inc. raised its position in Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock valued at $60,000 after purchasing an additional 475 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in Henry Schein by 58.9% during the third quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock worth $68,000 after purchasing an additional 346 shares in the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Price Performance

Shares of HSIC opened at $75.08 on Monday. The firm has a market capitalization of $9.36 billion, a price-to-earnings ratio of 30.90, a PEG ratio of 2.12 and a beta of 0.87. The firm’s fifty day simple moving average is $70.89 and its 200-day simple moving average is $69.73. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.63. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. The company had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. Henry Schein’s quarterly revenue was up .4% on a year-over-year basis. During the same period last year, the firm earned $1.32 earnings per share. Equities analysts forecast that Henry Schein, Inc. will post 4.78 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Michael S. Ettinger sold 12,240 shares of Henry Schein stock in a transaction on Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now directly owns 87,706 shares in the company, valued at $6,577,950. This trade represents a 12.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now owns 71,833 shares of the company’s stock, valued at $4,978,026.90. This represents a 22.65 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

HSIC has been the subject of a number of research reports. JPMorgan Chase & Co. dropped their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Barrington Research reiterated an “outperform” rating and set a $82.00 price target on shares of Henry Schein in a research note on Wednesday, November 6th. Robert W. Baird lowered their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Evercore ISI upped their target price on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Finally, StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Henry Schein presently has an average rating of “Moderate Buy” and an average target price of $78.89.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.